<DOC>
	<DOCNO>NCT00862992</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics efficacy 3 fixed dos MP-214 orally administer daily patient schizophrenia . MP-214 tablet administer patient start initial dose , follow up-titration fix dose ( low , medium high ) 14 day .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Efficacy Study MP-214 Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients meet DSMIVTR criterion schizophrenia PANSS total score &lt; = 120 observation period Patients treat oral antipsychotic within 4 week informed consent Patients whose consent obtain write form Patients define mental disorder `` Schizophrenia '' base criterion DSMIVTR History drug alcohol abuse Concurrent Parkinson 's disease History , concurrent spastic disorder like epilepsy , cerebrovascular disease , anuresis adynamic ( = paralytic ) ileus , malignant syndrome , diabetes , hepatic disorder Patients exhibit abnormality Physical Examination , abnormal vital sign , ECG , clinical laboratory value Current cataract observation period History shock anaphylactoid symptom drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>dopamine D3/D2 antagonist</keyword>
</DOC>